A NEW PHARMACEUTICAL CARE PROGRAM FOR COVID-19 PATIENTS TREATED WITH PAXLOVID®: IMPLEMENTATION AND SAFETY OUTCOMES REPORTED

Ferris Villanueva M, Chamorro de Vega E, Rodríguez-González C, Torroba Sanz B, Vicente Valor J, Herranz Alonso A, Sanjurjo Sáez M.
Servicio de Farmacia. Hospital General Universitario Gregorio Marañón. Madrid, Spain

BACKGROUND AND IMPORTANCE

Paxlovid® was granted an Emergency Use Authorization for the treatment of mild to moderate COVID-19. However, the use of Paxlovid® with certain other drugs in high-risk patients may result in potentially significant DDI and ADE.

AIM AND OBJECTIVE

To assess the impact of a comprehensive pharmaceutical care program (CPCP) focusing on the prevention of DDI and ADE, initiated in a hospital pharmacy for patients treated with Paxlovid®.

MATERIALS AND METHODS

• Quasi-experimental study performed between 1 of May and 31 of July of 2022.
• Pharmacists were responsible for proposing COVID-19 local guidelines to physicians, monitoring its adherence, managing DDI and ADE, providing patient education, and evaluating health outcomes.
• A telephone consultation was carried out 10 days after the end of Paxlovid® treatment.
• Potential DDI were detected according to Lexi-Comp® and Liverpool COVID-19 databases.
• Paxlovid-related ADE reported were graded according to Common Terminology Criteria for Adverse Events, version 4.

RESULTS

140 patients (60.7% outpatients) initiated Paxlovid® and were enrolled in the CPCP.

Pharmacists made 267 interventions that led to the prevention of 177 ADE (1.3/patient), 54.2% of which were grade G-H (NCC MERP classification).

DRUG-DRUG INTERACTIONS:

232 DDI were detected in 79.3% patients
61.2% of DDI required specific management:

✓ 34.5% discontinuation of the concomitant drug
✓ 65.5% dose adjustment

ADVERSE DRUG EVENTS:

At day 10, 96 ADEs were reported in 42 patients (26.1% of which were grade ≥3)

Most common ADEs were dysgeusia and diarrhea

Premature discontinuation of Paxlovid® due to ADEs was necessary in 4 (2.8%) patients.

CONCLUSION AND RELEVANCE

The implementation of a CPCP developed by hospital pharmacists for patients treated with Paxlovid® was an effective approach for monitoring adherence to guidelines, managing DDI, providing patient education, and evaluating safety outcomes.

Paxlovid® showed an acceptable safety profile.

maria.ferris@salud.madrid.org
@farma_gregorio
www.madrid.org/hospitalgregoriomaranon/farmacia

5PSQ-119